Zubi Capital
The Terminal Hub – C. de la Travesía, Valencia, Comunidad Valenciana, 46024, Spain
Overview
Zubi Capital is a dedicated and independent Asset Management and Wealth Management firm. We create innovative impact investment and advisory solutions that incorporate current and future environmental and social opportunities and risks, as we believe these will benefit from a competitive advantage and improved long-term financial prospects. We view impact investing as an integral part of any asset class and a core part of an enlightened investor’s overall portfolio.
- Total investments
- 15
- Lead investments
- 6
- Investments · 12mo
- 3
- Active investors
- 3
Sector focus
- Diabetes
- Financial Services
- Health Care
- Impact Investing
- Social
- Sustainability
Investment portfolio
- Humara
Participated · Seed · May 2026
Founded in 2021 in Galicia, Humara offers a physics-based SaaS platform for waste infrastructure with two main products: Humara Design for engineering and plant design, and Humara Operate which creates real-time Digital Twins for daily plant management. Its simulation engine models 82 distinct waste materials through real separation equipment, claiming to compress design cycles from roughly four months to days. Humara Operate integrates live SCADA signals, optical sorter data, and operational KPIs and includes an AI copilot called Duplantis for operator decision support. Early deployments reportedly deliver a 4% reduction in landfill reject rates, 4% higher material recovery, an estimated €800k annual profit uplift, and 5–7% lower OpEx per plant. The company says it has designed over 250 plants across Europe and Latin America and counts customers such as Veolia, FCC, PreZero, EGF, Ecoembes, and Bianna, which report cost savings and improved bidding capabilities.
- Predictheon
Participated · Equity · Apr 2026
Predictheon is developing an artificial intelligence platform aimed at giving anesthesiologists a single screen with the information they need and the ability to warn of imminent complications. The company was founded by Dr. Pedro Gambús together with physicians Sebastián Jaramillo and Jose Fernando Valencia, and is led by CEO Eva Gubern. Current plans focus on obtaining regulatory approval, initiating clinical trials and running additional pilot deployments, with a target of reaching a minimum market state around 2028. The startup has a small team of nine people and expects modest headcount growth to about 10–11 this year. Financially, it recently secured €1.8 million to fund these next development and commercialization steps. Predictheon is already engaging in discussions with large medical-equipment companies about potential partnerships, distribution deals or exits, and the company does not intend to handle a global commercial strategy entirely on its own.
- one • fıve
Participated · Series A · Jan 2026
Headquartered in Hamburg, one.five offers an AI-driven solution that converts technical performance data, regulatory constraints, and consumer preferences into precise requirement profiles for new packaging materials. This data-centric approach is designed to cut R&D waste and shorten time-to-market for sustainable paper-based packaging. The company was founded by Martin Weber, former CFO of vertical-farming unicorn Infarm, and Claire Hae-Min Gusko. Early commercial traction includes collaborations with paper manufacturers Starkraft (a Zellstoff Pöls AG unit) and Grünperga Papier, while it is also cultivating partnerships with converters and global FMCG brands. The recently secured Series A funding will finance further platform development and international operational expansion. Although no revenue or user numbers were disclosed, the company positions itself as a critical technology layer within the packaging supply chain, aiming to deliver market-ready, regulation-compliant materials more efficiently.
- Matteco
Participated · Series A · Oct 2024
Matteco develops patented platinum-free materials, catalytic coatings, and electrodes for renewable hydrogen production via alkaline electrolysis and AEM, aiming to reduce both capital and operating costs. Its materials claim lower energy consumption in electrolysers, higher current densities, and improved stability and durability. The company is a spin-off from the University of Valencia and part of Zubi Labs. Matteco already sells to customers in Europe, North America and Asia. It plans to open and ramp up a 10,000 sqm catalyst and electrode factory in Paterna (Valencia) to produce the equivalent of 1 GW of electrodes per year. The company intends to grow its team from 30 to 100 employees in 2025 as it scales production and commercial activity. Matteco develops nanotechnology-based catalysts and electrodes for alkaline and anion-exchange membrane (AEM) electrolysis. The company supplies high-performance components intended to increase efficiency and reduce the cost of green-hydrogen production. Matteco is partnering with Spanish manufacturer ARIEMA Energía y Medioambiente (ARIEMA ENERXIA SL) to integrate its components into a new generation of alkaline electrolyzers. The collaboration is embodied in the EMMA project, which has secured public funding to deploy next‑generation electrolyzer technology. Matteco says the step strengthens its position as a world-class supplier and comes on the eve of opening a gigawatt factory in Valencia. No operating metrics or revenue figures are disclosed in the article.
- Ancilia Biosciences
Participated · Equity · Aug 2024
Ancilia Biosciences develops virus-resistant live bacterial products for human health and other applications using proprietary CRISPR-based technologies. Its CoVE™ platform identifies and characterizes viral phages, and its EPIC platform leverages bacteria’s natural CRISPR function to produce live biotherapeutics and microbial products with immunity to key viral pathogens. The company has achieved proof-of-concept and holds key patents protecting these inventions. Led by CEO Alexandra Sakatos and co-founded by Dr. Rodolphe Barrangou and David Paez-Espino, the team combines expertise in CRISPR, virology, and bioinformatics. Ancilia intends to use the $4.2M financing to expand operations and its R&D sector. The company is based in New York City.